Site-specific conjugation for fully controlled glycoconjugate vaccine preparation by Pillot, Aline et al.
ORIGINAL RESEARCH
published: 01 November 2019
doi: 10.3389/fchem.2019.00726
Frontiers in Chemistry | www.frontiersin.org 1 November 2019 | Volume 7 | Article 726
Edited by:
Christoph Rademacher,











This article was submitted to
Chemical Biology,
a section of the journal
Frontiers in Chemistry
Received: 28 July 2019
Accepted: 10 October 2019
Published: 01 November 2019
Citation:
Pillot A, Defontaine A, Fateh A,
Lambert A, Prasanna M, Fanuel M,
Pipelier M, Csaba N, Violo T,
Camberlein E and Grandjean C (2019)
Site-Specific Conjugation for Fully
Controlled Glycoconjugate Vaccine
Preparation. Front. Chem. 7:726.
doi: 10.3389/fchem.2019.00726
Site-Specific Conjugation for Fully
Controlled Glycoconjugate Vaccine
Preparation
Aline Pillot 1,2, Alain Defontaine 1, Amina Fateh 1, Annie Lambert 1, Maruthi Prasanna 1,3,
Mathieu Fanuel 4, Muriel Pipelier 2, Noemi Csaba 3, Typhaine Violo 1, Emilie Camberlein 1
and Cyrille Grandjean 1*
1Université de Nantes, CNRS, Unité Fonctionnalité et Ingénierie des Protéines (UFIP), UMR 6286, Nantes, France,
2Université de Nantes, CNRS, Chimie Et Interdisciplinarité: Synthèse, Analyse, Modélisation (CEISAM), UMR 6230, Nantes,
France, 3Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Center for Research in Molecular
Medicine and Chronic Diseases (CIMUS), School of Pharamacy, Health Research Institute of Santiago de Compostela (IDIS),
University of Santiago de Compostela, Santiago de Compostela, Spain, 4Unité Biopolymères Interactions Assemblages
Plate-Forme BIBS, INRA, Nantes, France
Glycoconjugate vaccines are formed by covalently link a carbohydrate antigen to a
carrier protein whose role is to achieve a long lasting immune response directed
against the carbohydrate antigen. The nature of the sugar antigen, its length, its
ratio per carrier protein and the conjugation chemistry impact on both structure and
the immune response of a glycoconjugate vaccine. In addition it has long been
assumed that the sites at which the carbohydrate antigen is attached can also have
an impact. These important issue can now be addressed owing to the development
of novel chemoselective ligation reactions as well as techniques such as site-selective
mutagenesis, glycoengineering, or extension of the genetic code. The preparation and
characterization of homogeneous bivalent pneumococcal vaccines is reported. The
preparation and characterization of homogeneous bivalent pneumococcal vaccines
is reported. A synthetic tetrasaccharide representative of the serotype 14 capsular
polysaccharide of Streptococcus pneumoniae has been linked using the thiol/maleimide
coupling chemistry to four different Pneumococcal surface adhesin A (PsaA) mutants,
each harboring a single cysteine mutation at a defined position. Humoral response of
these 1 to 1 carbohydrate antigen/PsaA conjugates have been assessed in mice. Our
results showed that the carbohydrate antigen-PsaA connectivity impacts the anti-carrier
response and raise questions about the design of glycoconjugate vaccine whereby the
protein plays the dual role of immunogen and carrier.
Keywords: glycoconjugate vaccine, cysteine mutagenesis, chemoselective ligation, protein conjugation,
pneumococcal vaccine, thio/maleimide ligation
INTRODUCTION
Surface exposed polysaccharides of bacterial pathogens are perceived as non-self by the host
immune system. Therefore, they are often the target of a protective humoral immune response.
Immunization using polysaccharides from capsulated bacteria has been introduced by Gotschlich
in the late 1960s (Gotschlich et al., 1972). Capsular polysaccharides are typical T cell-independent
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type 2 antigens (Mond et al., 1995). This group of antigens
is able to deliver prolonged and persistent signaling to the
B cell through B cell receptor cross-linking. However, these
vaccines fail to be active in children, the population which is
the major target of the infectious diseases caused by pathogenic
bacteria. A major breakthrough in the field has been later
achieved by the development of the glycoconjugate vaccines
(Rappuoli, 2018). A purified capsular polysaccharide or a
fragment thereof or a synthetic oligosaccharide mimicking the
antigenic determinants expressed by capsular polysaccharide is
conjugated to a protein scaffold referred to as carrier protein.
In this case, the protein moiety of the conjugate is processed by
carbohydrate antigen-specific B cells after engagement of their
B cell receptor. This leads to the presentation of peptides—T
helper epitopes—in association with major histocompatibility
complex of type II (MHCII) molecules to carrier peptide-
specific CD4+ T lymphocytes. These T helper cells, in turn,
stimulate the production of both plasma cells andmemory B cells
(Pollard et al., 2009). This vaccine strategy proved highly efficient
even in infants. Consequently several vaccines active against
meningococcus, streptococcus, or Haemophilus influenza type b
have been launched (Berti and Adamo, 2018). Alternatively it has
recently been shown that a carbohydrate epitope presented in the
form of a glycopeptide by the MHCII molecules could strongly
stimulate CD4+ T cells (Avci et al., 2011; Berti and Adamo, 2013).
While both mechanisms probably coexist, this discovery might
considerably impact the design of future glycoconjugate vaccines.
Indeed, it has long been established that both length and density
of the carbohydrate antigens on the carrier protein influence
the immunogenicity of the conjugates in an interconnected
manner. At a fixed sugar/protein ratio, the anti-carbohydrate
antigen titers vary according to a bell curve as a function of
density (Pozsgay et al., 1999). On the other hand, the observed
optimum depends on the length of the antigen, this value
being usually lowered when one increases the chain length
(Anderson et al., 1989). However, if second mechanism has to
be considered, the selection of the glycosylation sites is equally
important. Along this line, Peng et al. have taken advantage
of the propensity of flagellin to self-assemble in a supercoiled
structure to selectively modify the sole lysines exposed to the
solvent and thus preserving the protein properties to activate
immune response (Peng et al., 2018). Stefanetti et al. recently
prepared a series of glycoconjugates made of CRM197 and
Salmonella O-antigen as the carrier protein and the carbohydrate
antigen, respectively (Stefanetti et al., 2015). An average of
one up to four O-antigen chains per protein was introduced
at controlled positions. The O-antigen chains were randomly
linked to surface accessible glutamic/aspartic acid or lysine
residues or at more defined sites upon exploiting the kinetically
favored reactivity of lysines having the lowest pKa (Crotti et al.,
2014; Matos et al., 2018), the rarity of surface exposed tyrosine
selectively activated (Hu et al., 2013; Nilo et al., 2014), the
transglutaminase catalyzed modification of a lysine (Nilo et al.,
2015b) or upon designing stapled conjugate from a reduced
disulfide bond. This study was useful to demonstrate that the
conjugation site plays a role in determining the immunogenicity.
However, the tested formulations still contained heterogeneous
mixtures of conjugates since the derivatization processes remain
largely empirical. Moreover, further discrepancies arose from
structural differences among the linkers used in the study
although the same strain promoted azide-alkyne cycloaddition
reaction was applied for the preparation of every conjugate.
Such biases do not allow an unequivocal interpretation of
observed results. Yet recent progress made in unnatural
amino acid incorporation (Quast et al., 2015), protein glycan
coupling technology (PGCT) (Ma et al., 2018) or site-selective
mutagenesis (Grayson et al., 2011) offer unique opportunities
to access fully defined glycoconjugate vaccines and further
elucidate the relationship between carbohydrate antigen/carrier
protein connectivity and immunogenicity. We report herein
the preparation and the characterization of homogeneous
bivalent pneumococcal conjugates. A synthetic tetrasaccharide
derived from Streptococcus pneumoniae serotype 14 capsular
polysaccharide equipped of a maleimido-functionalized spacer
arm at its reducing end has been site-specifically attached to four
different cysteine mono-mutants of the Pneumococcal surface
adhesin A (PsaA).
RESULTS AND DISCUSSION
Conjugate Design, Synthesis, and
Characterization
Pneumococcal infections are still a leading cause of mortality
worldwide. Available prophylactic pneumococcal glycoconjugate
vaccines induce capsule-specific memory B-cells and IgG capable
to prevent colonization and disease (Jochems et al., 2017).
Vaccine effectiveness is considerably improved by increasing the
valency e.g., from 7 up to 13 serotypes (van der Linden et al.,
2016). However, inclusion of serotype-independent immunogens
able to control pneumococcal carriage to these vaccines has been
identified as an appealing strategy (Jochems et al., 2017). PsaA is
a nasopharyngeal colonization factor which is expressed by more
than 99% of pneumococcal strains in a highly conserved form
(Rajam et al., 2008a). These features have thus designed PsaA as
a possible protein immunogen candidate (Wang et al., 2010; Gor
et al., 2011; Olafsdottir et al., 2012; Lu et al., 2015). Concomitant
administration of PsaA with PCV7 was accompanied with
reduced colonization in amurinemodel (Whaley et al., 2010) and
its protective effect in association with a panel of pneumococcal
protein immunogens later assessed in phase I clinical trials
(Schmid et al., 2011; Entwisle et al., 2017). Moreover, the
successful use of PsaA both as an immunogen and a carrier
protein PsaA by several laboratories including ours in mice
models further encouraged us to select it as a model protein (Lin
et al., 2010; Chen et al., 2016; Prasanna et al., 2019). Mature PsaA
(mPsaA) i.e., PsaA deprived from its signal peptide, was therefore
conjugated to the tetrasaccharide β− D−Galp− (1 → 4)− β−
D − Glcp− (1 → 6)− [β − D − Galp− (1 → 4)]β-D-GlcpNAc
1 (referred to as Pn14TS) (Figure 1A). This easily synthesized
tetrasaccharide is the minimal structure from the capsule of
serotype 14, one of the prevalent pneumococcal serotype which
has developed high antibiotic resistance (Yahiaoui et al., 2018),
able to induce functional antibodies (Abs) (Safari et al., 2008).
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FIGURE 1 | (A) Structure of tetrasaccharide antigen 1 from S. pneumoniae serotype 14 capsule and its activation with a maleimide linker; reagents and conditions: (a)
3-maleimidopropionic acid N-hydrosysuccimide ester (1.45 equiv), DIEA (2 equiv), DMF, RT, overnight, 58%. (B) Ribbon diagram of PsaA (green). Regions containing
known Th and B-epitopes are colored in red. Lysine side-chain are represented in green except the four lysines targeted for mutagenesis (in blue). Representation
based on the 1PSZ PDB file, with a resolution of 2.0 Å (Lawrence et al., 1998).
We observed that while high anti-mPsaA Ab titers were induced
in mice immunized with mPsaA alone, this response was much
lower when mice where immunized with a conjugate whereby
Pn14TS was randomly coupled to surface-exposed lysine side-
chains of mPsaA at a 5.4:1 average value for carbohydrate:protein
ratio (Prasanna et al., 2019). This observation might result
from mPsaA B epitope masking due to Pn14TS conjugation
on the protein, immune-dominance of antigenic determinants
expressed by Pn14TS over the mPsaA B epitopes or different
processing of free vs. conjugated mPsaA. Developing an
access to homogeneous Pn14TS-mPsaA conjugates will therefore
provide tools to address these issues and document structure-
immunogenicity relationships useful for future pneumococcal
vaccine design.
mPsaA is a 32.4 kDa-protein which corresponds to amino
acids 21-309 of PsaA sequence. mPsaA essentially adopts alpha-
helical secondary structures and contains 37 lysines, most of
them accessible for conjugation (Figure 1B) (Couñago et al.,
2014). Interestingly, mPsaA does not contain any cysteine residue
which makes site-selective cysteine mutagenesis an attractive
approach to envision homogenous mPsaA conjugate synthesis
(Grayson et al., 2011). Previous studies based on secondary
structure predictions, endopeptidase site analyses and in silico
MCHII peptide-binding affinity screening helped identifying
a panel of 24 putative PsaA T-helper epitopes. Three out
of them proved to be able to provoke Th cell proliferation:
PsaA67−82, PsaA199−221, and PsaA231−268. The last one was
deduced from three potent overlapping 15-mer peptides among
which sequence 243–257 was the most potent (Singh et al.,
2014). Identification of PsaA B epitopes has also been carried
out using a phage display peptide library and monoclonal Abs.
Two sequences in the region 132–146 and 253–267 showed
promises for their immunogenicity in mice noticeably for
reducing carriage and colonization (Srivastava et al., 2000;
Johnson et al., 2002). Further studies have demonstrated that the
sequence PsaA251−278 was involved in PsaA-mediated adherence
of S. pneumoniae to epithelial cells (Romero-Steiner et al., 2006;
Rajam et al., 2008b). In view of these data, we elected to
mutate C-terminal lysine 309 located in an apparently non-
relevant region for immunity into a cysteine. The preparation
of three additional cysteine mutants at K237, K242, and K247
i.e., within or close to the potent T-helper epitope was also
envisaged (Figure 1B).
We have recently reported the production in Escherichia coli
BL21(DE3) of the mPsaA N-terminated by a poly-6-histidine tag
sequence to facilitate its purification by immobilized-Ni affinity
chromatography plus a Tabacco Etch Protease (TEV) specific
cleavage site to remove the tag after purification (Prasanna et al.,
2019). mPsaA production level has been increased by 5–6 fold
upon adopting time/temperature/induction conditions reported
by Laurentis et al. and replacing the LB by the TB growth
medium (Supplementary Figure 1 and Supplementary Table 1)
(Larentis et al., 2011). The four mutants have been produced
accordingly after having introduced every desiredmutation in the
original sequence using the QuickChange method. Culture have
been carried out at a 250ml scale and yielded about 19mg of each
mutant after purification and histidine tag removal (Figure 2).
Having the four mutants in hand we next examined their
respective conjugation with the carbohydrate antigen. To this
aim, known tetrasaccharide 1 (Prasanna et al., 2019) was
derivatized with a maleimide linker to provide 2 in 58% yield
following RP-HPLC purification (Figure 1A). The four mutants
were treated separately with DTT to reduce any inter-protein
disulfide bondwhichmight have formed during their preparation
and further reacted with no more than 5 equivalent of 2 in
degassed PBS, pH 7.0 at room temperature overnight. Each
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FIGURE 2 | mPsaA K309C characterization as a representative example.
Analysis of histidine tag removal from mutant mPsaA K309C by SDS-PAGE
(A) and by Western blot (B). Lane 1: unstained protein marker; Lane 2: tagged
mPsaA K309C; Lane 3: purified mPsaA K309C after removal of poly-histidine
tag.
conjugate was then subjected to gel filtration purification to
remove excess tetrasaccharide (Figure 3) and freeze-dried for
storage. Gel filtration chromatography profiles of conjugates
associated to mPsaA K237C, K242C, and K247C were very
similar and essentially composed of a single peak. A second
unidentified peak which is eluted earlier is apparent in the
Pn14TS-mPsaA K309C profile (Figure 3). We first thought that
it corresponds to a dimer of the mPsaA K309C whose formation
had been favored due to a greater exposure of the cysteine
at the C-terminus. However, mass spectrometry experiments
ruled out this hypothesis. Effectiveness of the conjugation was
checked by gel electrophoresis which uniformly showed that
spots are shifted toward higher molecular weight, compatible
with the attachment of a single tetrasaccharide (Figure 4A).
These results were confirmed by MALDI mass spectrometry
experiments which indicate that parent mutant mPsaA proteins
were incremented by 896–906 mass unit (calculated +901 Da)
within the error range mass measurements (Figure 4B). In
the end homogenous 1:1 carbohydrate antigen/carrier protein
K237C, K242C, K247C, K309C conjugates have been obtained
in 55, 36, 44, and 30% yield, respectively, with a purity superior
to 90%.
Humoral Response Evaluation
Groups of five C57/BL6 mice were immunized thrice at 2
weeks interval with each of the four conjugates and PBS
as a negative control formulated in chitosan and Ribi as
adjuvant. The antibody response against both mPsaA and
capsular polysaccharide of S. pneumoniae serotype 14 (CP14),
was then determined by ELISA assays 1 week after the second
and third immunization (i.e., on Days 21 and 35). The IgG
response raised against CP14 by the conjugates was very low
and not significant compared to the negative control group
(data not shown). This response was equally low when we used
FIGURE 3 | Comparison of size exclusion chromatography profile of
Pn14TS-mPsaA K247C (red trace) and Pn14TS-mPsaA K309C (Black trace)
conjugates. Column HiLoad 15/600 SuperdexTM 75 pg (GE Healthcare)
column and PBS 0.1M, pH 7.3 as eluent.
Pn14TS as the coating antigen indicating that the observed
results were not due to a lack of recognition of CP14 by anti-
Pn14TS Abs. Anti-CP14 IgM response was also determined after
the second and the third immunizations. Low titers of anti-
CP14 IgM Abs could be measured in the sera of mice for
any of the tested formulations after the second immunization
(Supplementary Figure 2A). Highest titers of anti-CP14 Abs
seem to be induced by Pn14TS-mPsaA K247C conjugate in
comparison with other conjugates and PBS. Pn14TS-mPsaA
K309C gave rise to the weakest response comparable to that
induced by PBS. However, these tendencies were not statistically
significant. Anti-IgM responses further diminished after the
boost although the expected IgM to IgG switch was not observed
(Supplementary Figure 2B). In fact, we and other experienced
in the past that Pn14Ts was able to efficiently mimic native CP14
(Safari et al., 2008; Kurbatova et al., 2017; Prasanna et al., 2019).
However, as mentioned in the introduction, it is assumed that
the level of the anti-carbohydrate antigen response depends on
intricate related parameters such as carbohydrate antigen length,
carbohydrate antigen:carrier (S/P) ratio and administered sugar
dose (Pozsgay et al., 1999). For examples, significant humoral
response has been previously observed against Pn14TS: this
hapten being used at a S/P ratio of 4, at a 2.5 µg dose using
adipic acid coupling chemistry and CRM197 as the carrier (Mawas
et al., 2002); at a S/P ratio of 4.8 or 6, at a 2.5 µg dose,
using squarate coupling chemistry and CRM197 as carrier protein
(Mawas et al., 2002; Safari et al., 2008); at a S/P ratio of 11, at
1.25–10 µg dose, using squarate chemistry and BSA as carrier;
at a S/P ratio of 5.4, at 3 µg dose using thio/maleimide coupling
chemistry and PsaA as carrier protein. Testing of Pn14TS at a
S/P of 1 is unprecedented. Absence of anti-CP14 IgG response
might be circumvented upon increasing the length of the antigen.
Effective response was nicely observed when a dodecasaccharide
(corresponding to 3 × Pn14TS units), conjugated to CRM197
was used in a 1:1 carbohydrate antigen/carrier protein ratio
(Safari et al., 2008). Increasing the administered dose could also
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FIGURE 4 | Analysis of bioconjugation efficiency by SDS PAGE and mass spectrometry. (A) Comparison of each mPsaA mutant before, mix of before and after, and
after conjugation. Lanes 1–3: mPsaA K237C; Lanes 4–6: mPsaA K247C; Lanes 7–9: mPsaA K242C; Lanes 10–12: mPsaA K309C. Two micrograms protein
sample/lane, 12% SDS-PAGE, 100V, 2 h; (B) MALDI MS spectrum of mPsaA K309C (top spectrum) and Pn14TS-mPsaA K309C (bottom spectrum).
FIGURE 5 | Titers of anti-mPsaA (coated on microtiter plates) IgG Abs of mice immunized with Pn14TS-mPsaA K237C, K242C, K247C, K309C, PBS 1 week after
the 2nd (J21) (A) and the 3rd (J35) immunization (B). The serum samples data presented as geometric mean titer ± standard deviation of five mice per group.
Statistical analysis was performed using one-way ANOVA with Tukey analysis for multiple comparisons. Statistical difference between the groups is *P < 0.05.
been envisaged. A very low amount of carbohydrate antigens
(0.5 µg/dose/mouse) was indeed used for immunizations. This
value was chosen to keep the amount of injected mPsaA
equal to 25 µg/dose/mouse and remaining coherent with our
previous experiments (Prasanna et al., 2019). The adopted
strategy was nevertheless applicable to the investigation of
the anti-mPsaA response. IgM Ab response was absent in all
tested sera in agreement with our previous findings (data not
shown) (Prasanna et al., 2019). Contrasting with these results
a significant response was observed in the secondary sera of
mice immunized with the conjugates in comparison with the
control group (P < 0.05) (Figure 5A). Level of anti-mPsaA
IgG titers was further raised up to 1/8,000–1/64,000 for all
sera after the third immunization. The highest titers were
observed in sera of mice immunized with Pn14TS-mPsaA K242C
and K309C. Noticeably, anti-mPsaA IgG Abs induced by the
later conjugate was significantly higher than those induced by
Pn14TS-mPsaA K237C or Pn14TS-mPsaA K247C (P < 0.05)
but not Pn14TS-mPsaA K242C (Figure 5B). We have recently
shown that mPsaA was highly immunogenic in mice while
introduction of only five tetrasaccharide haptens by classic
lysine random conjugation severely impaired its immunogenicity
(Prasanna et al., 2019). Maintaining the protective properties of
the mPsaA epitopes is of paramount importance if a dual role of
both vaccine immunogen and carrier for carbohydrate antigens
is envisaged. Dual anti-Group B Streptococcus glycoconjugate
vaccines have been prepared using transglutaminase or tyrosine-
directed conjugation technology. This coupling strategy was
shown to preserve the antigenicity of the Streptococcus proteins
used as the carriers (Nilo et al., 2014). Immunogenicity of the
conjugates with defined connectivity was essentially comparable
to that observed for conjugates obtained upon conjugation of
surface-exposed lysine side-chains (Nilo et al., 2015a,b). In a
different study, PGCT was applied to the controlled transfer
of E. coli O157:H7 O-polysaccharide to the asparagine residue
amino acid sequence (DQNAT)4 introduced at the C-terminus
of the maltose-binding protein used as carrier protein model
(Ma et al., 2018). The glycosylation had slight interference on
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the global anti-MBP response. However, for the first time it
has been shown that the carbohydrate antigen decreased the
response against the peptides containing or adjacent to the
polysaccharide but not against peptide at distal site. Our results
are in agreement with these data. Immunogenicity of mPsaA
is globally conserved but finely tuned by the grafting of a
single carbohydrate antigen. The highest anti-mPsaA response is
observed when Pn14TS is introduced at position 309 of mPsaA
i.e., in a peptide segment distant from the identified T-helper
epitope and not when it is introduced at position 237, 242,
or 247. This result makes sense if mPsaA B-cell epitopes and
Pn14TS antigen compete for the assistance of the same T-helper
epitopes. CRM197 remains the best carrier protein develop so far
for use in humans. Structural alteration of the epitopes expressed
by CRM197 during conjugation and detoxification processes
have been proposed to explain its superiority as a carrier
protein over diphtheria toxoid or tetanus toxoid (Pecetta et al.,
2015). Beyond, if one cannot improve the response against one
antigen at the detriment of the response against another equally
important one then the strategy consisting in using a protein
with dual role of antigen and carrier is questionable. Consistent
with this assumption, the weakest anti-Pn14TS response was
measured in sera of mice immunized with the Pn14TS-mPsaA
K309C conjugate. However, further studies are required to
confirm this tendency since the anti-CP14 titers were weak and
limited to IgM Abs. In a study based on the use of group B
streptococcal type III polysaccharide, it has been calculated that
approximately eight repeat units of a polysaccharide branched
to a T-helper peptide could be presented in complex with
a MCHII molecule to a T-cell receptor (TCR) (Avci et al.,
2011).We herein elected to work with a short tetrasaccharide
antigen. It is conceivable that a TCR can recognize both our
small carbohydrate antigen and part of the T-helper peptide
sequence even though this is not yet demonstrated. Access to
longer synthetic oligosaccharides is more demanding from the
synthetic aspect and not necessarily associated with improved
antigenicity (Safari et al., 2008). Also the use of purified CP
will be accompanied by a loss of conjugate homogeneity while
complexing its immune investigation. However, administration
of a higher dose of sugar might improve the response against
the Pn14TS and allow assessment of the variation of both anti-
sugar and anti-protein responses. Alternatively, such study could
be envisaged upon coupling not one but several carbohydrate
antigen at controlled positions. Further work is also needed to
assess the protective properties of the Abs and to investigate in
detail the B-cell response, in particular which part of the protein
is targeted by the humoral response.
CONCLUSION
The development of technologies based on site-directed or
site-specific conjugation for example relying on cysteine
mutagenesis as exemplified in this study can lead to fully
characterized glycoconjugate vaccines while ensuring
higher batch-to-batch reproducibility. Moreover, it offers
unique opportunity to study structure-immunogenicity
relationship while unraveling molecular aspects of the immune




Mutations K237C, K242C, K247C, and K309C have been
performed by PCR amplification Phusion polymerase (Thermo
Scienyific), followed by DpnI digestion using the following
primers: K237C forward 5′-GCACCCCGGAGCAAATCT
GCACCCTGGTGGAAAAGC, reverse 5′-GCTTTTCCACCA
GGGTGCAGATTTGCTCCGGGGTGC; K242C forward 5′-
CAAATCAAAACCCTGGTGGAATGCCTGCGTCAGACCAA
AGTTCCG, reverse 5′-CGGAACTTTGGTCTGACGCAGG
CATTCCACCAGGGTTTTGATTTG; K247C forward 5′- GAA
AAGCTGCGTCAGACCTGCGTTCCGAGCCTGTTCGTG,
reverse 5′-CACGAACAGGCTCGGAACGCAGGTCTGACG
CAGCTTTTC; K309C forward 5′-GGAGGGTCTGGCGTGC
TAAGGATCCGGC, reverse 5′-GCCGGATCCTTAGCACGCCA
GACC CTCC. The plasmids obtained are then transformed into
competent XL1 blue bacteria. For each mutation, extraction
of the plasmid (Quiaprep R©Miniprep from Quiagen) on three
different clones is carried out according to manufacturer
protocol, and insertion of the mutations checked by sequencing.
Mutant mPsaA Expression
The validated plasmids have been used to transform E. coli
BL21 (DE3) strains for expression of the different mutants. The
expression of mPsaA mutant proteins was performed according
to the following protocol. Briefly, 250mL of fresh TB medium
with 100µg/ml ampicillin were inoculated with 0.5mL of
overnight pre-culture and left to grow at 37◦C, 180 rpm until
they reach the exponential phase (approximately OD of 0.6/0.7
is reached) and at this point the HtTEV-mPsaA expression in the
cultures were induced with IPTG (0.1mM final concentration).
The cultures were left to grow for another 16 h at 25◦C and
180 rpm. The cells were harvested at 10,000 rpm. The pellet
were re-suspended in 25ml cold lysis buffer (50mM NaH2PO4,
150mM NaCl, pH 8.0 + 5mM Imidazole + 1mM PMSF) +
1µg/mL DNAse, and 1 mg/mL of lysozyme incubated at 4◦C
under stirring during 30min and were subjected to sonication
(7min, 50% amplitude, pulse of 5 s ON/OFF) while they were
kept in ice, and the cell debris were removed by centrifugation
(30min, 13,000 rpm). The obtained supernatant was filtered
(0.45µm) and incubated with 0.5ml of preconditioned Ni NTA
beads for 1 h on rotating disk at 4◦C, 12 rpm. Unbound fraction
was collected, and the beads were washed with a lysis buffer
containing 2–10mM imidazole. The elution was performed with
a lysis buffer containing 300mM imidazole. The eluted fractions
were subjected to SDS-PAGE to identify the fractions containing
target protein. Later, the eluted fractions, containing the target
protein (100 mg/L of culture), were pooled and dialyzed against
water at 4◦C.
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Removal of Poly-6-Histidine Tag and
Western Blot Analysis
The enzymatic cleavage of the histidine tag from mutants was
performed using a 5:1 HtTEV-mPsaA/AcTEVTM protease ratio
in the reaction buffer (50mM Tris-HCl (pH 7.6), 1mM EDTA,
1mM DTT), for 16 h at 20◦C, without stirring. The crude
reactionmixtures were then dialyzed against water and incubated
with the Ni NTA beads for the separation of the cleaved mPsaA
mutants from the histidine tag, parent mPsaA mutants if not
entirely digested and the tagged TEV protease. The eluate was
collected and was subjected to SDS-PAGE and western blot
analyses to confirm the removal of the histidine tag and assess
their purity.
For the western blot, the vertical SDS-PAGE was carried out
using 12% acrylamide gels with the loadings of the reaction
mixture and tagged mPsaA mutants as controls using the Bio-
rad system. The proteins were transferred to a nitrocellulose
membrane at 150mA for 90min. For the antibody probing,
the nitrocellulose membrane was initially blocked with TBS
containing 5% skim milk and 0.1% tween 20 for 1 h at RT. A
primary antibody to mouse anti-poly histidine (Sigma H1029,
diluted 1:1,000), was applied to the membrane and incubated
for 16 h at RT with agitation. The membranes were washed
thrice with PBS containing 0.1% tween 20 and incubated with
secondary antibody (Goat anti-Mouse IgG (H+L) Secondary
Antibody, Alexa Fluor 680) for 1 h at RT on a shaker. Membranes
were subjected to a final wash with PBS, and the detection
was performed using an Odyssey CLx scanner (LI-COR)
at 700 nm.
2-(N-3-maleimidopropanoyl)ethyl(β − d −
galactopyranosyl) − (1 → 4) − (β − d −
galactopyranosyl) − (1 → 6) − [(β − d −
galactopyranosyl) − (1 → 4)] − 2 − deoxy −
2 − acetamido− β-d-glucopyranoside 2
To a solution of 2-amino-ethyl (β − D − galactopyranosyl) −
(1 → 4) − (β − D − galactopyranosyl) − (1 → 6) −
[(β − D − galactopyranosyl) − (1 → 4)] − 2 − deoxy − 2 −
acetamido − β-D-glucopyranoside 1 (17.5mg, 0.023 mmol, 1
equiv) in DMF were successively added 3-maleimido-propionic
acid succinimidyl ester (9mg, 1.45 equiv) and DIEA (8.30
µL, 2 equiv) at RT. The reaction mixture was stirred at RT
overnight, diluted in water and freeze-dried. The crude residue
was purified by RP-HPLC to provide 2 (12.2mg, 58% yield);
Rf 0.39 (nBuOH/EtOH/H2O 5:5:3);
1H NMR (400 MHz, D2O):
δ 6.85 (s, 2H), 4.52 (d, J = 8.2Hz, 1H), 4.51 (d, J = 7.8Hz,
2H), 4.43 (d, J = 7.8Hz, 1H), 4.26 (dd, J = 1.9, 11.7Hz, 1H),
3.99–3.88 (m, 4H), 3.84–3.62 (m, 20H), 3.60–3.55 (m, 1H), 3.54–
3.48 (m, 2H), 3.36 (ddd, J = 2.5, 7.8, 9.8Hz, 1H), 3.28 (t, J =
4.1Hz, 2H), 2.48 (t, J = 7.0Hz 2H), 2.00 (s, 3H); 13C NMR
(100 MHz, D2O): δ 174.7, 173.5, 172.6, 134.5, 103.0, 102.8, 102.5,
101.2, 78.5, 77.9, 75.4, 75.3, 74.7, 74.3, 73.5, 72.7, 72.6, 72.6, 72.4,
71.0, 71.0, 68.9, 68.6, 68.2, 67.4, 61.1, 61.0, 60.2, 55.1, 39.3, 34.7,




mPsaA mutants proteins are rehydrated with ultrapure water
to reconstitute 50mM phosphate buffer. The pH are tested
and adjusted to pH 8 with NaOH 0.1M if necessary. mPsaA
solutions are then treated with DTT (1.6 mg/mg of protein).
Solutions are mixed first by flush and next let in rotary shaker at
room temperature for 15min. DTT is eliminated with desalting
column (Zeba Spin, 7 MWCO) prior equilibrated with degassed
pH 7 PBS buffer using swing centrifuge. Protein contents are
quantified using Nanodrop spectrophotometer at 280 nm prior
their conjugation. To a solution of mPsaA mutants (4.8–7.2mg)
in degassed 40mM PBS, pH 7.0 (1.8–2.4 mg/mL), was added
2 (5 equiv) dissolved in water (1 mg/mL), and the resulting
mixture stirred overnight and then purified by gel filtration using
a HiLoad 15/600 SuperdexTM 75 pg (GE Healthcare) column
and 0.1M PBS, pH 7.3 as eluent at 0.8 ml/min. Collected
fractions were concentrated by centrifugal concentrators (cut-
off 3 MWCO) (Vivaspin; 1 h 7,000 g 4◦C) and then freeze-dried
to give the corresponding conjugates which were analyzed for
identity and purity by gel electrophoresis and mass spectrometry.
Immunizations
The conjugates (40 µl of a 5 mg/ml solution in PBS), were first
formulated with a mixture of chitosan/poloxamer/TPP (1:1:1)
(6mL) under stirring (600 rpm) for 30min. The particles were
concentrated by centrifugation at 12000 RCF for 12min at
15◦C, using 10 µL of glycerol bed. After the centrifugation,
the pellet in the bottom is carefully collected and re-suspended
in PBS (50 µL). The Groups of 5 male C57/BL6JRj (5
week old) mice were injected sub-cutaneously (s.c.) with PBS,
Pn14TS-mPsaA K237C, Pn14TS-mPsaA K242C, Pn14TS-mPsaA
K247C, or Pn14TS-mPsaA K309C (25 µg protein/dose-−0.5
µg tetrasaccharide/dose) diluted with 50 µL of RIBI in PBS.
The mice were immunized at day 0, 14, and 28. The sera were
collected on days 21 and 35. Sera were stored at−80◦C.
Measurement of Humoral Response
The Ab responses induced upon immunizations were assessed 1
week after the second and the third injections by ELISA. mPsaA
and capsular polysaccharide serotype 14 (CP14) (Alliance Bio
Expertise), were used as coated antigens to define the anti-mPsaA
or anti-CP14 Ab titers. mPsaA (0.1 µg/well) in 10mM PBS,
pH 7.3 (100 µL/well), was coated on 96 wells microtiter plates
Nunc Maxisorp (ThermoFisher Scientific) plates overnight at
4◦C. CP14 (1 µg/well) was coated for 48 h at 4◦C in 10mM PBS,
pH 7.3 (100 µL/well). Plates were then washed with PBS 0.05%
Tween 20 (3 × 200 µL), saturated using PBS containing 10%
skimmed milk at 37◦C for 2 h, then washed using PBS Tween
20 (PBST, 50mM Tris, 150mM NaCl, 0,1% Tween 20) (3 × 200
µL). Series of dilution of sera in PBS containing 10% skimmed
milk (100 µL/well), were incubated at 37◦C for 2 h. Plates were
then washed with PBST (3 × 200 µL) and then incubated
with goat anti-mouse IgG(H+L)-horse radish peroxidase-labeled
conjugate (CliniSciences) used as secondary Ab at a dilution
of 1/6,000, for 1 h at 37◦C and further washed with PBST
(5 × 200 µL). The enzyme substrate, o-phenylenediamine
dihydrochloride (100µL at 0.4mgmL−1) in 0.1M sodium citrate
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(pH 5.2), containing 0.02% hydrogen peroxide, was added to each
well and the plate incubated for 20min at RT in the dark. The
reaction was terminated by adding 3M HCl (1,000 µL per well),
and the A492 was read in an Infinite M1000 spectrophotometer
(TECAN). The Ab titer was defined as the dilution of immune
serum that gave an OD (405 nm) at least twice that observed with
pre-immune serum.
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